Halozyme Therapeutics (HALO) FCF Margin Growth (3y) (2013 - 2026)

Halozyme Therapeutics (HALO) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 15,064.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 723.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1,409.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Halozyme Therapeutics 9.55 Bn 9.23 Bn 297.47 Mn -658.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -658.00
Dec 31, 2025 403.00
Sep 30, 2025 1,672.00
Jun 30, 2025 449.00
Mar 31, 2025 1,738.00
Dec 31, 2024 -1,974.00
Sep 30, 2024 -6,736.00
Jun 30, 2024 -121.00
Mar 31, 2024 -92.00
Dec 31, 2023 -433.00
Sep 30, 2023 5,303.00
Jun 30, 2023 2,381.00
Mar 31, 2023 7,387.00
Dec 31, 2022 9,340.00
Sep 30, 2022 9,242.00
Jun 30, 2022 9,431.00
Mar 31, 2022 4,861.00
Dec 31, 2021 6,428.00
Sep 30, 2021 18,470.00
Jun 30, 2021 7,664.00